Prognostic markers in resected large cell neuroendocrine carcinoma: A multicentre retrospective analysis

Publikation: Beitrag in FachzeitschriftForschungsartikelBeigetragenBegutachtung

Beitragende

  • Christian Roesel - , Krankenhaus Bethanien Moers (Autor:in)
  • Stefan Welter - , Lungenklinik Hemer Deutscher Gemeinschafts-Diakonieverband GmbH (Autor:in)
  • Karl Otto Kambartel - , Krankenhaus Bethanien Moers (Autor:in)
  • Gerhard Weinreich - , Universität Duisburg-Essen (Autor:in)
  • Thomas Krbek - , Krankenhaus Bethanien Moers (Autor:in)
  • Monika Serke - , Lungenklinik Hemer Deutscher Gemeinschafts-Diakonieverband GmbH (Autor:in)
  • Mohammed Ibrahim - , Lungenklinik Hemer Deutscher Gemeinschafts-Diakonieverband GmbH (Autor:in)
  • Yazan Alnajdawi - , Universität Duisburg-Essen (Autor:in)
  • Till Plönes - , Universität Duisburg-Essen (Autor:in)
  • Clemens Aigner - , Universität Duisburg-Essen (Autor:in)

Abstract

Background: Large cell neuroendocrine carcinomas (LCNEC) are rare pulmonary malignancies. Reported survival rates are heterogeneous and the optimal therapeutic strategy is still debated. The prognosis of LCNEC is generally inferior compared to other non-small lung cancers. In early stages, surgery is recommended but might not be sufficient alone. Methods: We retrospectively analyzed all consecutive LCNEC patients operated at three institutions with curative intent between May 2005 and January 2017. Data retrieved from individual clinical databases were analyzed with the aim to identify prognostic parameters. Results: A total of 251 patients with LCNEC underwent curative intent surgery during the observation period. The median age was 64 years, 156 patients (62.2%) were male and 88.4% were smokers. The pathologic AJCC stage was I in 136 patients, II in 77, III in 33, and IV in 5 patients. Median followup was 26 months. Lymphatic vessel invasion (P=0.031) was identified as significant prognostic factor by multivariable analysis. There was a trend towards decreased survival in patients with blood vessel invasion (P=0.067). Even in earlier tumor stages, adjuvant chemotherapy had a positive effect on survival. The overall 1-, 3- and 5-year survival rates were 79.2%, 48.6% and 38.8% respectively. Conclusions: Lymphatic invasion (L1) is an independent prognostic factor. Surgery in LCNEC is beneficial in early tumor stages and platinum-based adjuvant chemotherapy may help in achieving better long-term outcomes resulting in most obvious survival differences in stage Ib.

Details

OriginalspracheEnglisch
Seiten (von - bis)466-476
Seitenumfang11
FachzeitschriftJournal of thoracic disease
Jahrgang12
Ausgabenummer3
PublikationsstatusVeröffentlicht - 1 März 2020
Peer-Review-StatusJa
Extern publiziertJa

Schlagworte

Ziele für nachhaltige Entwicklung

ASJC Scopus Sachgebiete

Schlagwörter

  • Curative resection, Large cell neuroendocrine carcinomas, Lymphatic invasion, Platinum-based adjuvant chemotherapy, Pulmonary malignancies